The 3′ UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer

Cancer Letters

Volumn 259, Issue 2, 2008, Pages 177-185

  Kotsinas, Athanassios ^a   Evangelou, Konstantinos ^a   Sideridou, Maria ^a   Kotzamanis, George ^a   Constantinides, Constantinos ^a   Zavras, Athanasios I ^b   Douglass, Chester W ^b   Papavassiliou, Athanasios G ^a   Gorgoulis, Vassilis G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

3 UTR polymorphism; IGF2R; NSCLC; p53

Indexed keywords

MITOGENIC AGENT; PROTEIN P53; SOMATOMEDIN B RECEPTOR; TP53 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ADVANCED CANCER; AGED; ALLELE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER STAGING; CAUCASIAN; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IGF2R A2 GENE; IGF2R B2 GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; SEQUENCE ANALYSIS; SHORT TANDEM REPEAT; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; ADENOCARCINOMA; CASE CONTROL STUDY; CHEMISTRY; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; LARGE CELL CARCINOMA; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK FACTOR;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTOR, IGF TYPE 2; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37149046822     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.013     Document Type: Article

References (25)

1. DaCosta S.A., Schumaker L.M., and Ellis M.J. Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate?. J. Mammary Gland Biol. Neoplasia 5 (2000) 85-94
2. Lee J.S., Weiss J., Martin J.L., and Scott C.D. Increased expression of the mannose 6-phosphate/insulin-like growth factor II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int. J. Cancer 107 (2003) 564-570
3. Xie S., and Kang J.X. Differential expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in human breast cancer cell lines of different invasive potential. Med. Sci. Monit. 8 (2002) BR293-BR300
4. Wang J., Richter K.K., Sung C.C., and Hauer-Jensen M. Upregulation and spatial shift in the localization of the mannose 6-phosphate/insulin-like growth factor II receptor during radiation enteropathy development in the rat. Radiother. Oncol. 50 (1999) 205-213
5. Kong F.M., Anscher M.S., Sporn T.A., Washington M.K., Clough R., Barcellos-Hoff M.H., and Jirtle R.L. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. Int. J. Radiat. Oncol. Biol. Phys. 49 (2001) 35-41
6. Iwamoto K.S., Yano S., Barber C.L., MacPhee D.G., and Tokuoka S. A dose-dependent decrease in the fraction of cases harboring M6P/IGF2R mutations in hepatocellular carcinomas from the atomic bomb survivors. Rad. Res. 166 (2006) 870-876
7. Iwamoto K.S., and Barber C.L. Radiation-induced posttranscriptional control of M6P/IGF2R expression in breast cancer cell lines. Mol. Carcinog. 46 (2007) 497-502
8. Zavras A.I., Pitiphat W., Wu T., Cartsos V., Lam A., Douglass C.W., and Diehl S.R. IGF2R-167 genotype increase the risk for oral squamous cell carcinoma in humans. Cancer Res. 63 (2003) 296-297
9. Zavras A.I., Douglas C.W., and Gorgoulis V.G. The role of IGF2R in carcinogenesis (Online correspondence). Nat. Rev. Cancer 4 (2004) 505-518
10. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., Zacharatos P., Kotsinas A., Liloglou T., Venere M., Ditullio Jr. R.A., Kastrinakis N.G., Levy B., Kletsas D., Yoneta A., Herlyn M., Kittas C., and Halazonetis T.D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434 (2005) 907-913
11. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C.L., Dyrskjot L., Ørntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T.D., Bartek J., and Gorgoulis V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444 (2006) 633-637
12. Takanami I., Imamuma T., Hashizume T., Kikuchi K., Yamamoto Y., Yamamoto T., and Kodaira S. Expression of PDGF, IGF-II, bFGF and TGF-beta 1 in pulmonary adenocarcinoma. Pathol. Res. Pract. 192 (1996) 1113-1120
13. Izycki T., Chyczewska E., Naumnik W., Talalaj J., Panek B., and Ossolinska M. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy. Exp. Oncol. 26 (2004) 316-319
14. Halazonetis T.D. Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer. DNA Repair 3 (2004) 1057-1062
15. Kong F.M., Anscher M.S., Washington M.K., Killian J.K., and Jirtle R.L. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 19 (2000) 1572-1578
16. Goto J., Figlewicz D.A., Marineau C., Khodr N., and Rouleau G.A. Dinucleotide repeat polymorphism at the IGF2R locus. Nucleic Acids Res. 20 (1992) 923
17. Hol F.A., Geurds M.P.A., Hamel B.C.J., and Mariman E.C.M. Improving the polymorphism content of the 3′ UTR of the human IGF2R gene. Hum. Mol. Genet. 1 (1992) 347
18. Killian J.K., Oka Y., Jang H.-S.J., Fu X., Waterland R.A., Sohda T., Sakaguchi S., and Jirtle R.L. Mannose 6-phospate/insulin-like growth factor 2 receptor (M6P/IGF2R) variants in American and Japanese populations. Hum. Mutat. 18 (2001) 25-31
19. Chen Z., Ge Y., Landman N., and Kang J.X. Decreased expression of the mannose 6-phosphate/insulin-like growth factor II receptor promotes growth of human breast cancer cells. BMC Cancer 2 (2002) 18-27
20. Souza R.F., Wang S., Thakar M., Smolinski S.N., Yin J., Zou T.T., Kong D., Abraham J.M., Toretsky J.A., and Meltzer S.J. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene 18 (1999) 4063-4068
21. Buerger H., Gebhardt F., Schmidt H., Beckmann A., Hutmacher K., Simon R., Lelle R., Boecker W., and Brandt B. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res. 60 (2000) 854-857
22. Contente A., Dittmer A., Koch M.C., Roth J., and Dobbelstein M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat. Genet. 30 (2002) 315-320
23. Kotsinas A., Gorgoulis V.G., Zacharatos P., Liloglou T., Leonardou P., Bramis J., Troupis T.G., Fotiadis C., Field J.K., and Kittas C. A new rare allele at the CGG repeat polymorphism in the first intron of human c-H-ras gene. In Vivo 15 (2001) 105-108
24. Kotsinas A., Gorgoulis V.G., Zacharatos P., Mariatos G., Kokotas S., Liloglou T., Ikonomopoulos J., Zoumpourlis V., Kyroudi A., Field J.K., Asimacopoulos P.J., and Kittas C. Additional characterization of a hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas. Cancer Genet. Cytogenet. 126 (2001) 147-154
25. Ledakis P., Tester T.W., Rosenberg N., Romero-Fischmann D., Daskal I., Lah T.T., and D C. B and L in malignant human lung tissue. Clin. Cancer Res. 2 (1996) 561-568